These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34737044)

  • 1. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
    Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
    Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors.
    Gustafsson G; Eriksson F; Möller C; da Fonseca TL; Outeiro TF; Lannfelt L; Bergström J; Ingelsson M
    Cell Mol Neurobiol; 2017 Jan; 37(1):121-131. PubMed ID: 26961542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
    Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
    Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease.
    Espay AJ; Lees AJ
    Parkinsonism Relat Disord; 2024 May; 122():106077. PubMed ID: 38461037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
    Alzghool OM; van Dongen G; van de Giessen E; Schoonmade L; Beaino W
    Mov Disord; 2022 May; 37(5):936-948. PubMed ID: 35289424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against alpha-synuclein: tools and therapies.
    Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
    J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.
    Lindström V; Fagerqvist T; Nordström E; Eriksson F; Lord A; Tucker S; Andersson J; Johannesson M; Schell H; Kahle PJ; Möller C; Gellerfors P; Bergström J; Lannfelt L; Ingelsson M
    Neurobiol Dis; 2014 Sep; 69():134-43. PubMed ID: 24851801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy.
    Chu WT; Hall J; Gurrala A; Becsey A; Raman S; Okun MS; Flores CT; Giasson BI; Vaillancourt DE; Vedam-Mai V
    ACS Chem Neurosci; 2023 Jan; 14(2):235-245. PubMed ID: 36571847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of copper transporter 1 prevents α-synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse model of Parkinson's disease.
    Gou DH; Huang TT; Li W; Gao XD; Haikal C; Wang XH; Song DY; Liang X; Zhu L; Tang Y; Ding C; Li JY
    Redox Biol; 2021 Jan; 38():101795. PubMed ID: 33232911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
    Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
    ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
    Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight.
    Upcott M; Chaprov KD; Buchman VL
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.